Leerink Partners Maintains a Buy on Lantheus Holdings (LNTH) With a $99 PT

Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth low PE stocks to invest in now. In a report released on August 21, Faisal Khurshid from Leerink Partners maintained a Buy rating on Lantheus Holdings, Inc. (NASDAQ:LNTH) and set a price target of $99.00.

Lantheus Holdings, Inc. (LNTH): Among Stocks with Consistent Growth to Buy Now

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported its fiscal Q2 2025 results on August 6, with worldwide revenue for the quarter reaching $378.0 million. GAAP fully diluted earnings per share were $1.12, and free cash flow reached $79.1 million for the quarter.

Lantheus Holdings, Inc. (NASDAQ:LNTH) also announced the FDA’s acceptance of NDA for a new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026.

Lantheus Holdings, Inc. (NASDAQ:LNTH) provides diagnostic imaging and nuclear medicine products, developing products that support healthcare professionals in patient management and outcomes and help clinicians detect cardiovascular disease. The company’s operations are divided into the U.S. and International geographical segments.

While we acknowledge the potential of LNTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LNTH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.